Alembic Pharmaceuticals share news, announcements and annual reports
NSE: APLLTDBSE: 533573Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 28 Oct 2026. Previous close ₹766.90.
28 Oct: open ₹769.95, high ₹788.00, low ₹765.90
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,387 Cr430th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.26
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.71
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.53%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,25,41753.6% delivered
Alembic Pharmaceuticals analyst meets
94 filed, newest first. Page 1 of 2.
Oct 2026
28 Oct · Analysts
Sep 2026
18 Sep · Analysts
Aug 2026
27 Aug · Analysts
27 Aug · Analysts
Jul 2026
Jun 2026
19 Jun · Analysts
19 Jun · Analysts
19 Jun · Analysts
May 2026
25 May · Analysts
Apr 2026
29 Apr · Analysts
Mar 2026
20 Mar · Analysts
6 Mar · Analysts
4 Mar · Analysts
Jan 2026
21 Jan · Analysts
Dec 2025
4 Dec · Analysts
4 Dec · Analysts
Oct 2025
27 Oct · Analysts
Aug 2025
29 Aug · Analysts
18 Aug · Analysts
Jul 2025
21 Jul · Analysts
Jun 2025
18 Jun · Analysts
May 2025
23 May · Analysts
20 May · Analysts
16 May · Analysts
Apr 2025
25 Apr · Analysts
Feb 2025
19 Feb · Analysts
Nov 2024
6 Nov · Analysts
Oct 2024
Aug 2024
27 Aug · Analysts
9 Aug · Analysts
Jul 2024
26 Jul · Analysts
26 Jul · Analysts
Apr 2024
18 Apr · Analysts
Feb 2024
13 Feb · Analysts
Jan 2024
18 Jan · Analysts
Oct 2023
16 Oct · Analysts
Aug 2023
16 Aug · Analysts
Jul 2023
21 Jul · Analysts
Jun 2023
1 Jun · Analysts
Apr 2023
26 Apr · Analysts
24 Apr · Analysts
Feb 2023
17 Feb · Analysts
Jan 2023
19 Jan · Analysts
Nov 2022
25 Nov · Analysts
1 Nov · Analysts
Sep 2022
8 Sep · Analysts
Aug 2022
8 Aug · Analysts
2 Aug · Analysts